ARN-509: a novel anti-androgen for prostate cancer treatment

Continued reliance on the androgen receptor (AR) is now understood as a core mechanism in castration-resistant prostate cancer (CRPC), the most advanced form of this disease. While established and novel AR-pathway targeting agents display clinical efficacy in metastatic CRPC, dose-limiting side effe...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Clegg, Nicola J., Wongvipat, John, Joseph, Jim, Tran, Chris, Ouk, Samedy, Dilhas, Anna, Chen, Yu, Grillot, Kate, Bischoff, Eric D., Cai, Ling, Aparicio, Anna, Dorow, Steven, Arora, Vivek, Shao, Gang, Qian, Jing, Zhao, Hong, Yang, Guangbin, Cao, Chunyan, Sensintaffar, John, Wasielewska, Teresa, Herbert, Mark R., Bonnefous, Celine, Darimont, Beatrice, Scher, Howard I., Smith-Jones, Peter, Klang, Mark, Smith, Nicholas D., De Stanchina, Elisa, Wu, Nian, Ouerfelli, Ouathek, Rix, Peter J., Heyman, Richard A., Jung, Michael E., Sawyers, Charles L., Hager, Jeffrey H.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2012
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3306502/
https://ncbi.nlm.nih.gov/pubmed/22266222
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-11-3948
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares